Global Next-Generation Antibody Therapies Market Forecast 2018-2028
The global next-generation antibody therapies market reached $4bn in 2017 and is estimated to reach $17bn by 2023. In 2017, the antibody-drug conjugates segment held 45% of the global next-generation antibody therapies market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 217-page report you will receive 141 charts– all unavailable elsewhere.
The 217-page report provides clear detailed insight into the next-generation antibody therapies market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
- Global Next-Generation Antibody Therapies Market from 2018-2028
- Forecast of the Global Next-Generation Antibody Therapies market by Submarket:
- Antibody Fragments & ALPs
- Antibody-Drug Conjugates
- Biosimilar Antibodies
- Bispecific Antibodies
- Engineered Antibodies
- Forecast of the Global Antibody Fragments & ALPs submarket by Product:
- Kalbitor
- Other Antibody Fragments
- Forecast of the Global Antibody-Drug Conjugates submarket by Product:
- Adcetris
- Kadcyla
- Mylotarg
- Other ADCs
- Forecast of the Global Biosimilar Antibodies submarket by Product:
- Infliximab
- Adalimumab
- Rituximab
- Bevacizumab
- Trastuzumab
- Other Biosimilar mAbs
- Forecast of the Global Bispecific Antibodies submarket by Product:
- Blincyto
- Hemlibra
- Other Bispecific Antibodies
- Forecast of the Global Engineered Antibodies submarket by Product:
- Gazyva/Gazyvaro
- Poteligeo
- Fasenra
- Other Engineered Antibodies
- This report provides individual revenue forecasts to 2028 for these regional and national markets:
- North America: US, Canada, and Mexico
- Europe: Germany, France, United Kingdom, Italy, Spain, Russia, and rest of Europe
- Asia-Pacific: Japan, China, Australia, South Korea, India, and rest of Asia-Pacific
- LAMEA: Brazil, Saudi Arabia, Republic of South Africa, Turkey, and rest of LAMEA
- Our study discusses the selected leading companies that are the major players in the next-generation antibody therapies market:
- Amgen, Inc.
- GlaxoSmithKline (GSK)
- Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.)
- Merck KGaA
- Novartis AG
- Pfizer, Inc.
- Roche
- Sanofi
- Seattle Genetics, Inc.
- Shire plc
- This report discusses SWOT & STEP analysis of the next-generation antibody therapies market as well as factors that drive and restrain this market. This report also discusses the opportunities that can be tapped in this market.
- This report also discusses selected at that are in the pipeline.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1 Global Next-Generation Antibody Therapies Market Overview
- 1.2 Global Next-Generation Antibody Therapies Market Segmentation
- 1.3 Why you Should Read this Report?
- 1.4 How this Report Delivers
- 1.5 Main Questions Answered by This Analytical Study
- 1.6 Who is This Report For?
- 1.7 Methodology
- 1.8 Frequently Asked Questions (FAQ)
- 1.9 Associated Reports
- 1.10 About Visiongain
- 2. Introduction to Next-Generation Antibody Therapies
- 2.1 Market Definition & Scope of this Report
- 2.2 Antibodies: An Overview
- 2.2.1 Monoclonal vs Polyclonal Antibodies
- 2.2.2 A Brief History of Antibody Drug Development
- 2.2.3 The Antibody Manufacturing Process
- 2.2.4 Trends in Antibody Development
- 2.3 Defining Next-Generation Antibodies
- 2.4 Classification of Next-Generation Antibody Therapies
- 2.5 The Need for Next-Generation Technologies
- 2.6 Development Trends for Next-Generation Antibodies
- 2.7 Phases of Clinical Trials
- 3. Global Next-Generation Antibody Therapies Market, 2017-2028
- 3.1 The Global Next-Generation Antibody Therapies Market Overview and Segmentation, 2017
- 3.2 Leading Next-Generation Antibody Therapies
- 3.3 Global Next-Generation Antibody Therapies Market: Sales Forecast 2017-2028
- 3.4 How Will Segments Market Shares Change to 2028?
- 3.5 Global Next-Generation Antibody Therapies Market: Drivers and Restraints 2017-2028
- 3.6 Global Next-Generation Antibody Therapies Market by Product Type, 2017-2028
- 4. Global Next-Generation Antibody Therapies Market by Product Type: Revenue Forecast, 2018-2028
- 4.1 Antibody-Drug Conjugates Submarket
- 4.1.1 Global Antibody-Drug Conjugates Submarket: Revenue Forecast, 2018-2028
- 4.2 Engineered Antibodies Submarket
- 4.2.1 Global Engineered Antibodies Submarket: Revenue Forecast, 2018-2028
- 4.3 Bispecific Antibodies Submarket
- 4.3.1 Global Bispecific Antibodies Submarket: Revenue Forecast, 2018-2028
- 4.4 Antibody Fragments and ALPs
- 4.4.1 Global Antibody Fragments and ALPs Revenue Submarket: Forecast, 2018-2028
- 4.5 Biosimilar Antibody Submarket
- 4.5.1 Global Biosimilar Antibody Submarket: Revenue Forecast, 2018-2028
- 4.6 Segment Share Analysis by Product Type
- 5. Global Next-Generation Antibody Therapies Market by Regional and National Market: Revenue Forecast, 2018-2028
- 5.1 Global Next-Generation Antibody Therapies Market by Region: Revenue Forecast, 2018-2028
- 5.2 North America
- 5.2.1 North America Next-Generation Antibody Therapies Market by Country: Revenue Forecast, 2018-2028
- 5.2.2 US Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.2.3 Canada Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.2.4 Mexico Next-Generation Antibody Therapies Market, Revenue Forecast, 2018-2028
- 5.3 Europe
- 5.3.1 Europe Next-Generation Antibody Therapies Market by Country: Revenue Forecast, 2018-2028
- 5.3.2 Germany Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.3.3 France Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.3.4 United Kingdom Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.3.5 Italy Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.3.6 Spain Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.3.7 Russia Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.4 Asia-Pacific
- 5.4.1 Asia-Pacific Next-Generation Antibody Therapies Market by Country: Revenue Forecast, 2018-2028
- 5.4.2 Japan Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.4.3 China Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.4.4 Australia Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.4.5 South Korea Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.4.6 India Next-Generation Antibody Therapies Market, Revenue Forecast, 2018-2028
- 5.5 LAMEA
- 5.5.1 LAMEA Next-Generation Antibody Therapies Market by Country: Revenue Forecast, 2018-2028
- 5.5.2 Brazil Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.5.3 Saudi Arabia Next-Generation Antibody Therapies Market: Revenue Forecast, 2018-2028
- 5.5.4 Republic of South Africa Next-Generation Antibody Therapies Market, Revenue Forecast, 2018-2028
- 6. Antibody-Drug Conjugates: Market Forecast and Pipeline 2017-2028
- 6.1 Market Overview
- 6.2 Leading ADCs in 2017
- 6.3 Antibody-Drug Conjugates: Market Forecast 2017-2028
- 6.4 Adcetris
- 6.4.1 Adcetris: Sales 2013-2017
- 6.4.2 Adcetris Results in AETHERA Trial and Approval for in HL following Stem Cell Transplantation
- 6.4.3 Expanding Adcetris Indications for Future Revenue Growth
- 6.4.4 Adcetris Sales Forecast 2018-2028
- 6.5 Kadcyla
- 6.5.1 Mixed Results from Different Clinical Trials
- 6.5.2 NICE Rejects Kadcyla on Cost Grounds, but it Just Manages to Hold on in the Cancer Drugs Fund List
- 6.5.3 Kadcyla Sales Forecast 2018-2028
- 6.6 Mylotarg
- 6.6.1 Mylotarg Sales Forecast 2018-2028
- 6.7 Antibody-Drug Conjugate Platforms
- 6.7.1 Radioconjugation
- 6.7.2 Seattle Genetics’ Platform
- 6.7.3 ImmunoGen: TAP Technology
- 6.7.4 Immunomedics
- 6.7.5 Preclinical Platforms for ADC Development
- 6.8 ADCs Have Attracted High-Value Deals and Will Continue to do so
- 6.9 Antibody-Drug Conjugates: Pipeline Analysis 2017-2028
- 6.9.1 The Longest Pipeline in the Next-Generation Antibodies Market
- 6.9.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
- 6.9.3 Seattle Genetics’ Phase 1 and Phase 2 ADCs
- 6.9.3.1 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer
- 6.10 Antibody-Drug Conjugates: Phase 3 Pipeline
- 6.10.1 CMC544 (inotuzumab ozogamicin, Pfizer)
- 6.10.1.1 Granted Breakthrough Therapy Designation
- 6.10.2 Roche Attempting to Expand Kadcyla Indications and also Possesses some Unique ADCs in the Pipeline
- 6.10.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL
- 6.11 Antibody-Drug Conjugates: Phase 2 Pipeline
- 6.11.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
- 6.11.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
- 6.11.3 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
- 6.11.4 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/ Seattle Genetics)
- 6.12 Antibody-Drug Conjugates: Phase 1 Pipeline
- 6.13 Antibody-Drug Conjugates: Preclinical Pipeline
- 6.14 Future Developments in ADC Technology
- 6.14.1 Site-Specific Linkage for Improved Safety Profiles
- 7. Engineered Antibodies: Market Forecast 2017-2028
- 7.1 Market Overview
- 7.2 Leading Engineered Antibodies in 2017
- 7.3 Engineered Antibodies: Market Forecast 2017-2028
- 7.4 Gazyva/Gazyvaro
- 7.4.1 Gazyva/Gazyvaro Sales Forecast, 2018-2028
- 7.5 Poteligeo
- 7.5.1 Poteligeo Sales Forecast, 2018-2028
- 7.6 Engineered Antibodies Platforms
- 7.6.1 Roche Glycart: GlucoMAb
- 7.6.2 Kyowa Hakko Kirin: Potelligent
- 7.6.3 Glycotope: GlycoExpress
- 7.6.4 MacroGenics
- 7.6.5 Xencor: XmAb
- 7.7 Engineered Antibodies: Phase 3 Pipeline
- 7.7.1 Ublituximab (anti-CD20, TG Therapeutics)
- 7.7.2 MEDI-551 (anti-CD19, AstraZeneca)
- 7.7.3 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
- 7.8 Engineered Antibodies: Phase 2 Pipeline
- 7.8.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
- 7.8.2 Margetuximab (anti-HER2, MacroGenics)
- 7.8.3 Teplizumab (anti-CD3, MacroGenics)
- 7.8.4 XmAb5871 (anti-CD19, Xencor)
- 7.9 Engineered Antibodies: Phase 1 Pipeline
- 8. Bispecific Antibodies: Market Forecast 2017-2028
- 8.1 Market Overview
- 8.2 Bispecific Antibodies: Market Forecast 2017-2028
- 8.3 Blincyto
- 8.3.1 Blincyto Sales Forecast, 2018-2028
- 8.4 Bispecific Antibodies Platforms
- 8.4.1 BiTE Platform
- 8.4.2 MacroGenics’ DART Platform
- 8.4.3 TriomAbs (TRION Pharma)
- 8.4.4 Other Bispecific Antibody Platforms
- 8.4.4.1 DuoBodies (Genmab)
- 8.4.4.2 ImmTAC (Immunocore)
- 8.5 Bispecific Antibodies: Pipeline Analysis 2017-2028
- 8.6 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
- 8.6.1 ABT-981 (anti-IL-1α and IL-1β, AbbVie)
- 8.6.2 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
- 8.6.3 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
- 8.6.4 SAR156597 (anti-IL-4 and IL-13, Sanofi)
- 8.7 Bispecific Antibodies: Phase 1, Phase 1/2 and Preclinical Pipeline
- 9. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast 2017-2028
- 9.1 Market Overview
- 9.2 Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast 2017-2028
- 9.3 Kalbitor
- 9.3.1 Kalbitor Sales Forecast, 2018-2028
- 9.4 Antibody Fragments and ALPs Platforms
- 9.4.1 Single-chain Variable Fragment Platforms
- 9.4.1.1 ESBATech and Delenex Therapeutics
- 9.4.1.2 Nanobodies: The Smallest Antibody Fragment
- 9.4.1.3 Ablynx’s Nanobody Platform
- 9.4.1.4 Domain Antibodies: GSK and Crescendo Biologics
- 9.4.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
- 9.4.2.1 DARPins: One-Tenth the Size of Antibodies
- 9.4.2.2 Anticalins (Pieris)
- 9.4.2.3 Affibodies (Affibody)
- 9.4.2.4 Fynomers (Covagen/Johnson & Johnson)
- 9.4.2.5 Affilins (Scil Proteins)
- 9.4.2.6 Adnectins (Bristol-Myers Squibb)
- 9.4.2.7 AdAlta: i-bodies
- 9.5 Antibody Fragments and ALPs: Pipeline Analysis 2017-2028
- 9.5.1 Ablynx Leads the Pipeline with Eight Clinical Projects
- 9.6 Antibody Fragments and ALPs: Phase 3 Pipeline
- 9.6.1 Caplacizumab (anti-vWF, Ablynx)
- 9.6.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)
- 9.7 ESBA1008 (anti-VEGF, Novartis)
- 9.8 Antibody Fragments and ALPs: Phase 2 Pipeline
- 9.8.1 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
- 9.8.2 Ozoralizumab (anti-TNFα, Ablynx )
- 9.8.3 DLX105 (anti-TNF-α, Delenex Therapeutics)
- 9.8.4 ALX-0171 (anti-respiratory syncytial virus)
- 9.8.5 PRS-080 (Pieris Pharmaceuticals GmbH)
- 9.9 Antibody Fragments and ALPs: Phase 1 Pipeline
- 9.9.1 ALX-0761/M1095 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
- 9.9.2 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
- 9.10 Other Phase 1 Candidates, and the Preclinical Pipeline
- 10. Biosimilar Antibodies: Market Forecast 2017-2028
- 10.1 Market Overview
- 10.2 Leading Biosimilar Antibodies in 2017
- 10.3 Biosimilar Antibodies: Market Forecast 2017-2028
- 10.4 Infliximab Biosimilar Sales Forecast, 2018-2028
- 10.5 Adalimumab Biosimilar Sales Forecast, 2018-2028
- 10.6 Rituximab Biosimilar Sales Forecast, 2018-2028
- 10.7 Trastuzumab Biosimilar Sales Forecast, 2018-2028
- 10.8 The Biosimilar Antibodies Market: Drivers and Restraints 2017-2028
- 10.8.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets
- 10.8.2 Rising Incidence of Cancer Will Drive Demand
- 10.8.3 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
- 10.8.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?
- 11. Leading Companies in Next-Generation Antibody Therapies Market
- 11.1 Seattle Genetics Inc.
- 11.1.1 Company Overview
- 11.1.2 Operating Segments
- 11.1.3 Financial Highlights
- 11.1.4 Product Pipeline
- 11.1.5 Recent Strategic Developments
- 11.2 F. Hoffmann-La Roche Ltd.
- 11.2.1 Company Overview
- 11.2.2 Operating Segments
- 11.2.3 Financial Highlights
- 11.2.4 Product Pipeline
- 11.2.5 Recent Strategic Developments
- 11.3 Pfizer, Inc.
- 11.3.1 Company Overview
- 11.3.2 Operating Segments
- 11.3.3 Financial Highlights
- 11.3.4 Recent Strategic Developments
- 11.4 Kirin Holdings (Kyowa Hakko Kirin Co., Ltd.)
- 11.4.1 Company Overview
- 11.4.2 Operating Segments
- 11.4.3 Financial Highlights
- 11.4.4 Recent Strategic Developments
- 11.5 Sanofi S.A.
- 11.5.1 Company Overview
- 11.5.2 Operating Segments
- 11.5.3 Financial Highlights
- 11.5.4 Recent Strategic Developments
- 11.6 Merck KGaA (Merck Sereno)
- 11.6.1 Company Overview
- 11.6.2 Operating Segments
- 11.6.3 Financial Highlights
- 11.6.4 Recent Strategic Developments
- 11.7 Amgen Inc.
- 11.7.1 Company Overview
- 11.7.2 Operating Segments
- 11.7.3 Financial Highlights
- 11.7.4 Recent Strategic Developments
- 11.8 Novartis AG
- 11.8.1 Company Overview
- 11.8.2 Operating Segments
- 11.8.3 Financial Highlights
- 11.8.4 Recent Strategic Developments
- 11.9 GlaxoSmithKline plc
- 11.9.1 Company Overview
- 11.9.2 Operating Segments
- 11.9.3 Financial Highlights
- 11.10 Shire plc
- 11.10.1 Company Overview
- 11.10.2 Operating Segments
- 11.10.3 Financial Highlights
- 12. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2017-2028
- 12.1 SWOT Analysis of the Next-Generation Antibody Therapies Market
- 12.1.1 Strengths: The Path Towards Market Acceptance
- 12.1.2 Weaknesses – Multiple Companies Targeting Similar Indications
- 12.1.2.1 Challenges Exist with Current Monoclonal Antibody Therapies
- 12.1.3 Opportunities: Novel Platforms
- 12.1.3.1 Big Pharmas are Investing Heavily in Next-Generation Pipelines
- 12.1.4 Threats: Entry of Biosimilars
- 12.1.4.1 Will Biosimilars Growth Slow Down in the Next-Generation Antibody Market?
- 12.2 Market Dynamics
- 12.2.1 Drivers
- 12.2.1.1 Rise in prevalence of cancer diseases
- 12.2.1.2 Increase in medical insurance coverage
- 12.2.1.3 Strong pipeline of drugs
- 12.2.2 Restraints
- 12.2.2.1 Risk of allergic reaction and limitations
- 12.2.2.2 Lengthy & stringent government regulations
- 12.2.3 Opportunities
- 12.2.3.1 Increasing R&D in cancer therapy
- 12.2.3.2 Increase in purchasing power of emerging economies
- 12.3 PEST Analysis of the Next-Generation Antibody Therapies Market
- 12.3.1 Political and Regulatory Issues
- 12.3.1.1 Regulatory Challenges for Biosimilar Antibodies
- 12.3.2 Economic Pressures
- 12.3.2.1 Next-Generation Antibodies Are High-Cost
- 12.3.2.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
- 12.3.2.3 Next-Generation Launches for Product Lifecycle Management
- 12.3.3 Social Factors
- 12.3.3.1 Cancer Incidence Is Rising Rapidly
- 12.3.3.2 Next-Generation Antibodies for Personalised Medicine
- 12.3.4 Technological Developments
- 12.3.4.1 There Are Many Competing Platforms
- 12.3.4.2 Manufacturing Challenges Exist for Most Sectors
- 12.3.4.3 New Analytical Tools for Target Identification and Protein Characterisation
- 12.4 Key Targets for Next-Generation Antibody Development 2017-2028
- 12.4.1 Oncology Is the Lead Indication in All Sectors
- 12.4.1.1 HER2 and HER3 for Breast Cancer
- 12.4.1.2 CD19 and CD20 for Lymphoma and Leukaemia
- 13. Conclusions
- 13.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 20167-2028
- 13.2 Current Status of the Market and Leading Segments
- 13.3 Leading Next-Generation Antibody Therapies Profiled in this Report
- 13.4 Leading Regional Markets
- 13.5 Development of the Market to 2028
- 13.6 Technology Platforms Will Continue to Attract Big Pharma Interest
- 13.7 Most Developers Continue to Target Cancer
- 13.8 Strategies for Growth in 2017-2028
- Appendices
- Associated Visiongain Reports
- Visiongain Report Sales Order Form
- About Visiongain
- Visiongain report evaluation form
- List of Tables
- Table 2.1 Monoclonal Antibody Types and Sources
- Table 2.2 The Different Phases of Clinical Trials and What They Assess
- Table 3.1 Global Next-Generation Antibody Therapies Market by Product: Revenue ($m) and Market Share (%), 2017
- Table 3.2 Global Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2017-2028
- Table 3.3 Global Next-Generation Antibody Therapies Market by Product: Revenue ($m) and Market Share (%), 2017 & 2028
- Table 4.1 Global Next-Generation Antibody Therapies Market by Product Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 4.2 Global Antibody-Drug Conjugates Submarket: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 4.3: Global Engineered Antibodies Submarket: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 4.4 Global Bispecific Antibodies Submarket: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 4.5 Global Antibody Fragments and ALPs Submarket: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 4.6 Global Biosimilar Antibody Submarket: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 4.7 Global Next-Generation Antibody Therapies Market by Product Type: Revenue ($m), Revenue Share (%), 2017, 2023, 2028
- Table 5.1 Global Next-Generation Antibody Therapies Market by Region: Revenue ($m), Revenue Share (%), 2017, 2023, 2028
- Table 5.2 Global Next-Generation Antibody Therapies by Leading National Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.3 North America Next-Generation Antibody Therapies Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.4 US Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.5 Canada Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.6 Mexico Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.7 Europe Next-Generation Antibody Therapies Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.8 Germany Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.9 France Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.10 United Kingdom Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.11 Italy Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.12 Spain Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.13 Russia Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.14 Asia-Pacific Next-Generation Antibody Therapies Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.15 Japan Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.16 China Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.17 Australia Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.18 South Korea Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.19 India Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.20 LAMEA Next-Generation Antibody Therapies Market by Country: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.21 Brazil Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.22 Saudi Arabia Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 5.23 Republic of South Africa Next-Generation Antibody Therapies Market: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 6.1 Antibody-Drug Conjugates Market by Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 6.2 Adcetris: Market Revenue ($m) 2013-2017
- Table 6.3 Adcetris Market Revenue ($m), AGR (%) and CAGR (%) 2018-2028
- Table 6.4 Kadcyla: Market Revenue ($m), AGR (%) and CAGR (%) 2018-2028
- Table 6.5 Mylotarg Market Revenue ($m), AGR (%) and CAGR (%) 2018-2028
- Table 6.6 Seattle Genetics ADC Collaborator Pipeline
- Table 6.7 Selected Preclinical ADC Development Platforms
- Table 6.8 ADC Pipeline by Major Indications, 2017
- Table 6.9 ADC Phase 3 Pipeline by Indication, 2018
- Table 6.10 Selected Ongoing Clinical Trials for CMC544 (inotuzumab ozogamicin), 2018
- Table 6.11 Roche’s Antibody-Drug Conjugates Pipeline, 2018
- Table 6.12 Selected Ongoing Clinical Trials for RG7596 (polatuzumab vedotin), 2018
- Table 6.13 ADC Phase 2 Pipeline by Indication, 2018
- Table 6.14 Selected Ongoing Clinical Trials for ABT-414, 2018
- Table 6.15 ADC Phase 1 Pipeline by Indication, 2018
- Table 6.16 ADC Preclinical Pipeline, 2018
- Table 7.1 Engineered Antibodies Market by Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 7.2 Gazyva/Gazyvaro Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
- Table 7.3 Poteligeo Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
- Table 7.4 Engineered Antibodies Phase 3 Pipeline by Indication, 2018
- Table 7.5 Selected Ongoing Clinical Trials for MEDI-551, 2018
- Table 7.6 Engineered Antibodies Phase 2 Pipeline by Indication, 2018
- Table 7.7 Selected Ongoing Clinical Trials for Margetuximab, 2018
- Table 7.8 Engineered Antibodies Phase 1 Pipeline by Indication, 2018
- Table 8.1 Bispecific Antibodies Market by Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 8.2 Blincyto: Market Revenue ($m), AGR (%) and CAGR (%) 2018-2028
- Table 8.3 Bispecific Antibodies Pipeline by Indication and Phase, 2017
- Table 8.4 Bispecific Antibodies Pipeline by Indication and Phase, 2018
- Table 8.5 Bispecific Antibodies: Phase 1/2 Pipeline, 2018
- Table 8.6 Bispecific Antibodies: Phase 1 Pipeline, 2018
- Table 8.7 Bispecific Antibodies: Preclinical Pipeline, 2018
- Table 9.1 Antibody Fragments and Antibody-Like Proteins (ALPs) Market by Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 9.2: Kalbitor Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
- Table 9.3 Antibody Fragments and ALPs Pipeline, 2018
- Table 10.1 Biosimilar Antibody Market by Type: Revenue ($m), AGR (%) and CAGR (%) 2017-2028
- Table 10.2 Infliximab Biosimilar Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
- Table 10.3 Adalimumab Biosimilar Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
- Table 10.4 Rituximab Biosimilar Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
- Table 10.5 Trastuzumab Biosimilar Market: Revenue ($m), AGR (%) and CAGR (%) 2018-2028
- Table 10.6 Patent Status of Five Leading mAbs
- Table 11.1 Seattle Genetics Inc. Operating Segments
- Table 11.2 Seattle Genetics Inc.: Revenue ($m), R&D ($m), 2015-2017
- Table 11.3 Seattle Genetics Inc. Product Pipeline
- Table 11.4 Seattle Genetics Inc. Recent Developments
- Table 11.5 Roche Operating Segments
- Table 11.6 Roche: Revenue ($m), R&D ($m), 2015-2017
- Table 11.7 Roche Product Pipeline
- Table 11.8 Roche Recent Developments
- Table 11.9 Pfizer Operating Segments
- Table 11.10 Pfizer: Revenue ($m), R&D ($m), 2015-2017
- Table 11.11 Pfizer Recent Developments
- Table 11.12 Kyowa Hakko Kirin Operating Segments
- Table 11.13 Kyowa Hakko Kirin: Revenue ($m), R&D ($m), 2015-2017
- Table 11.14 Kyowa Hakko Kirin Recent Developments
- Table 11.15 Sanofi Operating Segments
- Table 11.16 Sanofi: Revenue ($m), R&D ($m), 2015-2017
- Table 11.17 Sanofi Recent Developments
- Table 11.18 Merck Operating Segments
- Table 11.19 Merck: Revenue ($m), R&D ($m), 2015-2017
- Table 11.20 Merck Recent Developments
- Table 11.21 Amgen Operating Segments
- Table 11.22 Amgen: Revenue ($m), R&D ($m), 2015-2017
- Table 11.23 Amgen Recent Developments
- Table 11.24 Novartis Operating Segments
- Table 11.25 Novartis: Revenue ($m), R&D ($m), 2015-2017
- Table 11.26 Novartis Recent Developments
- Table 11.27 GSK Operating Segments
- Table 11.28 GSK: Revenue ($m), R&D ($m), 2015-2017
- Table 11.29: Shire Operating Segments
- Table 11.30: Shire: Revenue ($m), R&D ($m), 2015-2017
- List of Figures
- Figure 1.1 Global Next-Generation Antibody Therapies Market, Market Segmentation
- Figure 3.1 Global Next-Generation Antibody Therapies by Product: Market Share (%), 2017
- Figure 3.2 Global Next-Generation Antibody Therapies Market Forecast Revenue ($m) & AGR (%), 2017-2028
- Figure 3.3 Global Next-Generation Antibody Therapies Market by Product: Revenue ($m), 2028
- Figure 3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints, 2017-2028
- Figure 3.5 Global Next-Generation Antibody Therapies Market by Product: Revenue ($m), 2017-2028
- Figure 4.1 Global Antibody-Drug Conjugates Submarket: Revenue ($m), 2017-2028
- Figure 4.2 Global Engineered Antibodies Submarket: Revenue ($m), 2017-2028
- Figure 4.3 Global Bispecific Antibodies Submarket: Revenue ($m), 2017-2028
- Figure 4.4 Global Antibody Fragments and ALPs Submarket: Revenue ($m), 2017-2028
- Figure 4.5: Global Next-Generation Antibody Therapies Market, Biosimilar Antibody Revenue ($m), 2017-2028
- Figure 5.1 Global Next-Generation Antibody Therapies Market by Region: Revenue ($m), 2017-2028
- Figure 5.2 US Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.3 Canada Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.4 Mexico Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.5 Germany Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.6 France Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.7 United Kingdom Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.8 Italy Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.9 Spain Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.10 Russia Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.11 Japan Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.12 China Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.13 Australia Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.14 South Korea Next-Generation Antibody Therapies Market, Revenue ($m), 2017-2028
- Figure 5.15 India Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.16 Brazil Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.17 Saudi Arabia Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 5.18 Republic of South Africa Next-Generation Antibody Therapies Market: Revenue ($m), 2017-2028
- Figure 6.1 Antibody-Drug Conjugates Market Forecast: Revenue ($m) & AGR (%), 2017-2028
- Figure 7.1 Engineered Antibodies Market Forecast: Revenue ($m) & AGR (%), 2017-2028
- Figure 8.1 Bispecific Antibodies Market Forecast: Revenue ($m) & AGR (%), 2017-2028
- Figure 9.1 Antibody Fragments and Antibody-Like Proteins (ALPs) Market Forecast: Revenue ($m) & AGR (%), 2017-2028
- Figure 10.1 Biosimilar Antibody Market Forecast: Revenue ($m) & AGR (%), 2017-2028
- Figure 12.1 Next-Generation Antibody Therapies Market: Strengths and Weaknesses, 2017-2028
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook